[go: up one dir, main page]

AR008886A1 - Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea - Google Patents

Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea

Info

Publication number
AR008886A1
AR008886A1 ARP970104655A ARP970104655A AR008886A1 AR 008886 A1 AR008886 A1 AR 008886A1 AR P970104655 A ARP970104655 A AR P970104655A AR P970104655 A ARP970104655 A AR P970104655A AR 008886 A1 AR008886 A1 AR 008886A1
Authority
AR
Argentina
Prior art keywords
manufacture
inhibitor
pharmaceutical formulation
treatment
widal
Prior art date
Application number
ARP970104655A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR008886A1 publication Critical patent/AR008886A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de un inhibidor de H+,K+ -ATPasa en la fabricacion de un medicamento para el tratamiento de polipos nasales que comprende una cantidad efectiva dedicho inhibidor y un vehículo farmacéuticamente aceptable, uso de dicho inhibidor para la fabricacion de un medicamento para el tratamiento delsíndrome de Widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmacéutica y formulacion farmacéutica paraadministracion simultánea.
ARP970104655A 1996-10-11 1997-10-08 Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea AR008886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Publications (1)

Publication Number Publication Date
AR008886A1 true AR008886A1 (es) 2000-02-23

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104655A AR008886A1 (es) 1996-10-11 1997-10-08 Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea

Country Status (34)

Country Link
EP (1) EP0946175B1 (es)
JP (1) JP4100713B2 (es)
KR (1) KR100510812B1 (es)
CN (1) CN1146416C (es)
AR (1) AR008886A1 (es)
AT (1) ATE230597T1 (es)
AU (1) AU738310B2 (es)
BR (1) BR9711896A (es)
CA (1) CA2268305C (es)
CZ (1) CZ298799B6 (es)
DE (1) DE69718347T2 (es)
DK (1) DK0946175T3 (es)
EE (1) EE04043B1 (es)
ES (1) ES2188995T3 (es)
HK (1) HK1022848A1 (es)
HU (1) HUP0000036A3 (es)
ID (1) ID23692A (es)
IL (1) IL129324A0 (es)
IS (1) IS1930B (es)
MY (1) MY117918A (es)
NO (1) NO321007B1 (es)
NZ (1) NZ334786A (es)
PL (1) PL190902B1 (es)
PT (1) PT946175E (es)
RS (1) RS49599B (es)
RU (1) RU2197966C2 (es)
SA (1) SA97180641B1 (es)
SE (1) SE9603725D0 (es)
SK (1) SK284252B6 (es)
TR (1) TR199900770T2 (es)
TW (1) TW568784B (es)
UA (1) UA59374C2 (es)
WO (1) WO1998016228A1 (es)
ZA (1) ZA978842B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ES2310047T3 (es) 1998-08-18 2008-12-16 The Regents Of The University Of California Antagonistas del receptor del factor de crecimiento epidermico para el tratamiento de la hipersecrecion de mucosidad en los pulmones.
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
ATE487506T1 (de) * 1999-03-03 2010-11-15 Optinose As Nasales verabreichungsgerät
US20050020637A1 (en) * 2001-11-19 2005-01-27 Wolfgang-Alexander Simon Agents for the treatment of airway disorders
EP1487447A1 (en) * 2002-03-14 2004-12-22 ALTANA Pharma AG Use of proton pump inhibitors for the treatment of airway disorders
BR0309808A (pt) * 2002-05-07 2005-03-01 Altana Pharma Ag Combinação para o tratamento de distúrbios das vias aéreas
PL373000A1 (en) * 2002-05-07 2005-08-08 Altana Pharma Ag Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
RS51707B (sr) 2002-12-12 2011-10-31 Nycomed Gmbh. Kombinacija leka sastavljena od r, r - formoterola i ciklezonida
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5618452B2 (ja) 2003-09-16 2014-11-05 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングＴａｋｅｄａ ＧｍｂＨ 呼吸器疾患の治療のためのシクレソニドの使用
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델
JP7614938B2 (ja) 2021-05-11 2025-01-16 日立Astemo株式会社 サスペンション制御装置、およびサスペンション制御方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
ATE230597T1 (de) 2003-01-15
CA2268305C (en) 2006-11-28
WO1998016228A1 (en) 1998-04-23
SK284252B6 (sk) 2004-12-01
DE69718347T2 (de) 2003-08-28
SK38499A3 (en) 2000-03-13
NO991619L (no) 1999-04-06
CN1146416C (zh) 2004-04-21
MY117918A (en) 2004-08-30
JP2001508034A (ja) 2001-06-19
CZ122999A3 (cs) 1999-09-15
IS5021A (is) 1999-04-08
DK0946175T3 (da) 2003-03-17
HUP0000036A3 (en) 2003-02-28
TW568784B (en) 2004-01-01
EE04043B1 (et) 2003-06-16
YU16399A (sh) 2000-03-21
SE9603725D0 (sv) 1996-10-11
RU2197966C2 (ru) 2003-02-10
RS49599B (sr) 2007-06-04
AU4640997A (en) 1998-05-11
EP0946175B1 (en) 2003-01-08
CZ298799B6 (cs) 2008-02-06
JP4100713B2 (ja) 2008-06-11
NZ334786A (en) 2000-12-22
ZA978842B (en) 1998-04-14
EE9900118A (et) 1999-10-15
KR20000049046A (ko) 2000-07-25
IS1930B (is) 2004-05-18
HK1022848A1 (en) 2000-08-25
CA2268305A1 (en) 1998-04-23
TR199900770T2 (xx) 1999-06-21
ID23692A (id) 2000-05-11
KR100510812B1 (ko) 2005-08-31
NO321007B1 (no) 2006-02-27
IL129324A0 (en) 2000-02-17
NO991619D0 (no) 1999-04-06
CN1232397A (zh) 1999-10-20
SA97180641B1 (ar) 2005-12-18
ES2188995T3 (es) 2003-07-01
DE69718347D1 (de) 2003-02-13
AU738310B2 (en) 2001-09-13
EP0946175A1 (en) 1999-10-06
HU0000036D0 (es) 2002-05-29
BR9711896A (pt) 1999-08-24
PL332692A1 (en) 1999-09-27
PL190902B1 (pl) 2006-02-28
UA59374C2 (uk) 2003-09-15
HUP0000036A2 (hu) 2002-05-29
PT946175E (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
NZ288298A (en) Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
AP2003002922A0 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition.
SE0003449D0 (sv) Anticancer compositions
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
DE69828817D1 (de) Pharmazeutische aerosolzusammensetzungen
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
ATE292453T1 (de) Antivirale arznei
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
AR039408A1 (es) Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR9709316A (pt) Composição farmacêutica para administração tópica no tratamento da vaginite
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
ATE295169T1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist
DE69228686D1 (de) Topisch anzuwendendes arzneimittel enthaltend penciclovir
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
AR012872A1 (es) Uso del mometanosulfonato del acido (e)-alfa-[2-n-butil-1-[(carboxifenil)metil]-1-h-imidazol-5- il]metilen-2-tiofenpropionico para la fabricacion de un medicamento ycomposicion farmaceutica que lo comprende para tratar hipertension sistolica aislada.

Legal Events

Date Code Title Description
FB Suspension of granting procedure